{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-026871","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.875053+00:00","generated_at":"2026-06-04T05:53:32.829033+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aldeyra plans reproxalap NDA resubmission for dry eye disease in H2 2024","bullets":["Dry eye chamber trial to start H1 2024; NDA resubmission expected H2 2024 if positive.","FDA review period expected to be six months for potential resubmission.","Cash $142.8M as of Dec 31, 2023; projected to fund operations beyond 2026.","Primary endpoint: ocular discomfort; trial design from four prior reproxalap chamber trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-026871","json":"https://secwatch.observer/filing/0001213900-24-026871.json","markdown":"https://secwatch.observer/filing/0001213900-24-026871.md","text":"https://secwatch.observer/filing/0001213900-24-026871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/0001213900-24-026871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/ea0202743-8k_aldey.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:53:32.829033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}